Bedrocan launches Bedromed: standardised cannabinoid formulations derived from its trusted cannabis APIs

Bedrocan is proud to announce the launch of Bedromed, a new product line of standardised cannabinoid-based formulations. Leveraging Bedrocan’s decades of expertise in producing high-quality cannabis active pharmaceutical ingredients (APIs),  the Bedromed product line brings the trusted Bedrocan® and Bedrolina® cannabis APIs into new administration forms.

Bedromed spray & Bedromed drops

The Bedromed product line is designed to provide physicians and patients with a broad range of cannabinoid delivery methods that support precise dosing and streamlined administration. While other novel forms are expected to be included in the future, the initial Bedromed portfolio features two administration forms with a variety of THC:CBD ratios, including high-CBD, balanced, and high-THC options:

• Bedromed spray is a standardised cannabinoid-based formulation developed for sublingual administration and is based on Bedrocan® and Bedrolina® cannabis APIs.
• Bedromed drops is a standardised cannabinoid-based formulation developed for oromucosal administration and is based on Bedrocan® cannabis API.

Same trusted genetics

For over 20 years, Bedrocan has been known for consistency in medicinal cannabis production. Bedromed extends this legacy by offering Bedromed drops and Bedromed spray derived directly from the same trusted genetics and validated processes that have defined Bedrocan’s cannabis APIs.

CEO, Jaap Erkelens: “The launch of Bedromed is a significant expansion of our portfolio, allowing us to bring our trusted API closer to the patient alongside our core commitment to API supply. By offering new cannabinoid-based formulations, we ensure that the pharmaceutical-grade consistency we are known for is now accessible in modern, patient-appropriate delivery formats.”

Consistent pharmaceutical quality

All Bedromed products are manufactured in compliance with European good manufacturing practice (EU-GMP). Bedrocan guarantees full traceability from source plant to final product, with documented controls at each stage of the manufacturing process. This end-to-end oversight eliminates gaps in the supply chain and ensures consistent pharmaceutical quality across every batch.

Availability

The Bedromed product range will be available for distribution starting August 2026, with initial availability in Germany and further markets to follow.

For more information, contact our business team: